249 related articles for article (PubMed ID: 28724343)
1. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
Barrett PN; Terpening SJ; Snow D; Cobb RR; Kistner O
Expert Rev Vaccines; 2017 Sep; 16(9):883-894. PubMed ID: 28724343
[TBL] [Abstract][Full Text] [Related]
2. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
Barrett PN; Mundt W; Kistner O; Howard MK
Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
[TBL] [Abstract][Full Text] [Related]
3. Novel vaccine strategies against emerging viruses.
García-Sastre A; Mena I
Curr Opin Virol; 2013 Apr; 3(2):210-6. PubMed ID: 23477832
[TBL] [Abstract][Full Text] [Related]
4. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.
Hankaniemi MM; Laitinen OH; Stone VM; Sioofy-Khojine A; Määttä JAE; Larsson PG; Marjomäki V; Hyöty H; Flodström-Tullberg M; Hytönen VP
Vaccine; 2017 Jun; 35(30):3718-3725. PubMed ID: 28579231
[TBL] [Abstract][Full Text] [Related]
5. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development.
Chang JY; Chang CP; Tsai HH; Lee CD; Lian WC; Ih-Jen-Su ; Sai IH; Liu CC; Chou AH; Lu YJ; Chen CY; Lee PH; Chiang JR; Chong PC
Vaccine; 2012 Jan; 30(4):703-11. PubMed ID: 22142585
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.
Aichinger G; Ehrlich HJ; Aaskov JG; Fritsch S; Thomasser C; Draxler W; Wolzt M; Müller M; Pinl F; Van Damme P; Hens A; Levy J; Portsmouth D; Holzer G; Kistner O; Kreil TR; Barrett PN
Vaccine; 2011 Nov; 29(50):9376-84. PubMed ID: 22001875
[TBL] [Abstract][Full Text] [Related]
7. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges.
Delrue I; Verzele D; Madder A; Nauwynck HJ
Expert Rev Vaccines; 2012 Jun; 11(6):695-719. PubMed ID: 22873127
[TBL] [Abstract][Full Text] [Related]
8. Deinococcus Mn
Gayen M; Gupta P; Morazzani EM; Gaidamakova EK; Knollmann-Ritschel B; Daly MJ; Glass PJ; Maheshwari RK
Vaccine; 2017 Jun; 35(29):3672-3681. PubMed ID: 28576570
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
10. Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.
Li J; Liu G; Liu X; Yang J; Chang J; Zhang W; Yu XF
Viruses; 2015 Jul; 7(7):3891-909. PubMed ID: 26193302
[TBL] [Abstract][Full Text] [Related]
11. Measles-derived vaccines to prevent emerging viral diseases.
Frantz PN; Teeravechyan S; Tangy F
Microbes Infect; 2018; 20(9-10):493-500. PubMed ID: 29410084
[TBL] [Abstract][Full Text] [Related]
12. [Emerging viral diseases in Europe].
Löbermann M; Gürtler LG; Eichler-Löbermann B; Reisinger EC
Dtsch Med Wochenschr; 2012 Apr; 137(17):900-5. PubMed ID: 22511281
[TBL] [Abstract][Full Text] [Related]
13. Inactivated and subunit vaccines against porcine reproductive and respiratory syndrome: Current status and future direction.
Renukaradhya GJ; Meng XJ; Calvert JG; Roof M; Lager KM
Vaccine; 2015 Jun; 33(27):3065-72. PubMed ID: 25980425
[TBL] [Abstract][Full Text] [Related]
14. An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.
Wressnigg N; van der Velden MV; Portsmouth D; Draxler W; O'Rourke M; Richmond P; Hall S; McBride WJ; Redfern A; Aaskov J; Barrett PN; Aichinger G
Clin Vaccine Immunol; 2015 Mar; 22(3):267-73. PubMed ID: 25540268
[TBL] [Abstract][Full Text] [Related]
15. Cell substrates for the production of viral vaccines.
Aubrit F; Perugi F; Léon A; Guéhenneux F; Champion-Arnaud P; Lahmar M; Schwamborn K
Vaccine; 2015 Nov; 33(44):5905-12. PubMed ID: 26187258
[TBL] [Abstract][Full Text] [Related]
16. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
Erra EO; Kantele A
Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529
[TBL] [Abstract][Full Text] [Related]
17. Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases.
Xu Z; Ho M; Bordoloi D; Kudchodkar S; Khoshnejad M; Giron L; Zaidi F; Jeong M; Roberts CC; Park YK; Maslow J; Abdel-Mohsen M; Muthumani K
Methods Mol Biol; 2022; 2410():229-263. PubMed ID: 34914050
[TBL] [Abstract][Full Text] [Related]
18. Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.
Barrett PN; Portsmouth D; Ehrlich HJ
Expert Rev Vaccines; 2013 Apr; 12(4):395-413. PubMed ID: 23560920
[TBL] [Abstract][Full Text] [Related]
19. Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse.
Wu CY; Lin YW; Kuo CH; Liu WH; Tai HF; Pan CH; Chen YT; Hsiao PW; Chan CH; Chang CC; Liu CC; Chow YH; Chen JR
PLoS One; 2015; 10(8):e0136420. PubMed ID: 26287531
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory Antibodies Targeting Emerging Viruses: Advancements and Mechanisms.
Jin J; Simmons G
Clin Vaccine Immunol; 2016 Jul; 23(7):535-9. PubMed ID: 27226280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
